EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial

Chin Fen Neoh, Michelle K Yong, Leesa Rowley, Andrew W Roberts, Glen A Kennedy iD, Simon He, Anthony P Schwarer, Ian A Bilmon, Andrew H Wei, Monica A Slavin iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf385 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Chin Fen Neoh und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Antifungal Agents, Phenylurea Compounds. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Australian National Health, Leukaemia Foundation Australia, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To report the rates of proven, probable and possible invasive fungal disease (IFD) in patients receiving antifungal prophylaxis during initial induction and consolidation treatment of acute myeloid leukaemia (AML) plus either sorafenib or placebo.

Methods

As part of a randomized, double-blind trial of sorafenib or placebo in combination with intensive chemotherapy for newly diagnosed adult patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive AML (ALLG AMLM16 trial), liposomal amphotericin B (LAMB) prophylaxis was administered at 5 mg/kg twice weekly during induction and consolidation phases in both sorafenib and placebo treatment arms. Alternative prophylaxis was allowed per institutional practice once sorafenib/placebo treatment was completed. IFD episodes, reported as either a serious adverse event or an adverse event, were adjudicated.

Results

Of the 94 patients included for analysis of IFD, four IFD episodes (one proven and three possible) were reported during the induction treatment phase. The overall rate of proven/probable/possible IFD was 4.3% (4/94), with rates of 3.1% (2/64) and 6.7% (2/30) in the sorafenib and placebo groups, respectively. Seven patients had infusion-related reactions, and four were reported to be associated with LAMB administration.

Conclusions

LAMB with or without subsequent azole prophylaxis could be an alternative option for fungal prophylaxis for patients with AML in whom azoles are contraindicated or not tolerated. Sorafenib does not appear to be associated with an increased risk of IFD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3Antifungal AgentsPhenylurea CompoundsAntineoplastic AgentsNiacinamideInvasive Fungal InfectionsChemopreventionHumansSorafenibMiddle AgedMaleFemaleAdultDouble-Blind MethodAgedAmphotericin BPlacebosYoung AdultInduction ChemotherapyConsolidation Chemotherapy

Substanzen

Sorafenibfms-Like Tyrosine Kinase 3Antifungal AgentsFLT3 protein, humanPhenylurea Compoundsliposomal amphotericin BAmphotericin BPlacebosAntineoplastic AgentsNiacinamide

Autor:innen und Institutionen

  • National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
  • Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, Australia.
  • Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Australia.

ORCID-Profile: Glen A Kennedy, Monica A Slavin

Förderung

  • Australian National Health
  • Leukaemia Foundation Australia
  • Medical Research Council

Zitieren

APA

Neoh, C. F., Yong, M. K., Rowley, L., Roberts, A. W., Kennedy, G. A., He, S., Schwarer, A. P., Bilmon, I. A., Wei, A. H., & Slavin, M. A. (2025). Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf385

Vancouver

Neoh CF, Yong MK, Rowley L, Roberts AW, Kennedy GA, He S, et al. Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf385

BibTeX
@article{Neoh2025,
  author = {Neoh, Chin Fen and Yong, Michelle K and Rowley, Leesa and Roberts, Andrew W and Kennedy, Glen A and He, Simon and Schwarer, Anthony P and Bilmon, Ian A and Wei, Andrew H and Slavin, Monica A},
  title = {Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf385}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche